10900 University Blvd
Manassas, VA 20110

Our Mission

Our mission is to develop anti-inflammatory and immune-modulating drugs for treatment of a broad range of inflammatory, autoimmune and infectious diseases

The Team

Dr. Cohava Gelber, Founder and Executive Chairperson

Over 25 years experience in various executive positions in biotech and pharmaceutical companies (ImmuLogic Pharmaceutical Corp., Molecular Discoveries, MannKind Corp.); drug discovery and product development experience from non clinical stages, IND, through clinical development up to phase III clinical trials; secured over $500MM of federal funding; authored over 70 patents/patent applications; PhD from the Weizmann Institute, Post Doctorate at Stanford University and MBA from Cornell University.

Guy Yachin, Engineer and MBA, President & CEO

Entrepreneur and CEO of multiple biomedical companies; raised ~$100MM as CEO and Co-founder of Chiasma (announced a 600MM deal with Roche in February 2013) and MGVS (led it through a mega-deal with Teva Pharmaceuticals); has been an active board member of several successful private and public companies, among them Orgenesis (ORGS), Enzymotec, Remon Medical (acquired by BSC) and NanoPass.

Soren Mogelsvang, PhD, Founder and VP of Research and Development

15 years experience in discovery and translational research from various positions in biotech and academia. Dr. Mogelsvang holds a Ph.D. degree from the University of Cambridge, England, and received postdoctoral training at the University of Colorado School of Medicine.

Alexander Fleming, MD, President & CEO at Kinexum – Head of the SAB

World expert on diabetes; Co-Founder of Kinexum LLC – a leading strategic consulting organization in the cardiometabolic space. Serves on over a dozen clinical advisory boards for major pharmaceutical and biotech companies. FDA – 12 years, Head of Metabolic Group including diabetes, approved first statin, growth hormones, and all diabetes drugs in the 1990s. Represented FDA at international forums. Led professional education at CDER, FDA. CRO – 3 years Chief Scientific Officer, conducted drug trials worldwide, CRO sold to United Healthcare. Awarded his Doctorate of Medicine from Emory University, residency and fellowships at Vanderbilt University in endocrinology and NIH in metabolism

John Abeles, MD, Venture Investor, Director, Entrepreneur – Active board Member

Practiced medicine in London, before joining the pharmaceutical industry as a Senior Medical Executive with Sterling Drug, Pfizer, and Revlon Health Care. Became an industry analyst, and for over 35 years a prolific entrepreneur and venture investor. Played a key role in Encore Medical, acquired by Blackstone Capital; Newport Pharmaceuticals, acquired by Merck & Co.; Imre Corporation, acquired by Fresenius SE; ProCyte, acquired by PhotoMedex, and in many other public and private companies. Serves as an Advisory Board Member of the College of Chemistry, University of California, Berkeley and is a Fellow of the Royal Society of Medicine, London.